pazopanib — Medica
Uterine sarcoma
Initial criteria
- age ≥ 18 years
- recurrent or metastatic disease
- Patient has tried at least one systemic regimen (e.g., doxorubicin, docetaxel, gemcitabine, ifosfamide, dacarbazine, epirubicin, or vinorelbine)
Approval duration
1 year